SCHEMBL2322156

SCHEMBL2322156

COP(=O)(CC(=O)c1ccc(Cl)cc1Cl)OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
MAPK1 P28482 1/20 0.56
HIF1A Q16665 1/20 0.56
MAPT P10636 2/20 0.50
ERCC5 P28715 1/20 0.50
FEN1 P39748 1/20 0.50
KDM4E B2RXH2 1/20 0.50
POLB P06746 3/20 0.48
TDP1 Q9NUW8 2/20 0.48
THRB P10828 1/20 0.48
RECQL P46063 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TSHR P16473 1/20 0.47
CASP1 P29466 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
RAB9A P51151 2/20 0.47
CYP1A2 P05177 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2324762 0.88 ALDH1A1 (0.50) ALDH1A1MAPK1HIF1AMAPTERCC5
SCHEMBL2329635 0.86 FLT1 (0.43) ALDH1A1MAPK1HIF1AMAPTKDM4E
SCHEMBL1549680 0.85 PYGL (0.44) ALDH1A1MAPK1HIF1ARAB9AMEN1
SCHEMBL2322226 0.81 ERCC5 (0.47) ALDH1A1MAPTERCC5FEN1KDM4E
SCHEMBL11854969 0.79 POLB (0.60) ALDH1A1MAPTKDM4EPOLBTDP1
SCHEMBL1549850 0.79 HTT (0.46) MAPTKDM4ESMN1; SMN2RAB9ACYP1A2
SCHEMBL2322045 0.78 POLB (0.46) ALDH1A1MAPTPOLBRECQLSMN1; SMN2
SCHEMBL2322162 0.78 KMT2A (0.53) ALDH1A1MAPK1HIF1AMAPTERCC5
SCHEMBL9257364 0.77 LMNA (0.50) ALDH1A1MAPTERCC5FEN1KDM4E
SCHEMBL31114507 0.77 ALDH1A1 (0.62) ALDH1A1MAPK1HIF1AMAPTERCC5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904455-B1 PYRIDAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2011-08-17 EP disclosed
US-7678795-B2 Pyridazines as 11b-HSD1 inhibitors HOFFMAN-LA ROCHE INC. (US) 2010-03-16 US disclosed
EP-1904455-A2 PYRIDAZINE DERIVATIVES F. Hoffmann-Roche AG (CH) 2008-04-02 EP disclosed
WO-2007003521-A2 PYRIDAZINE DERIVATIVES AS 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2007-01-11 WO disclosed
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010519-A1 New pyridazines as 11B-HSD1 inhibitors HSD11B1, HSD17B1, HSD17B11 ALDH1A1 91/4885MAPK1 502/4885HIF1A 3630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.